EXECUTIVE SUMMARY
The global neurovascular intervention device market size is valued at an estimated 6.5 to 7.5 billion USD in 2026, with a compound annual growth rate of 7% to 11% through 2031. This expansion is underpinned by non-discretionary clinical demand linked to severe vascular pathologies. Globally, stroke remains a leading cause of mortality and permanent disability, accounting for 69.94 million ischemic strokes and 16.60 million intracerebral hemorrhage events each year, precipitating approximately 7.25 million deaths. Mainland China alone represents an epidemiological center of this burden, with over 28.0 million prevalent stroke survivors, an annual incidence ranging between 3.70 million and 3.94 million cases, and annual mortality exceeding 1.80 million individuals.

PRODUCT TAXONOMY AND ENGINEERING ARCHITECTURE
A neurovascular intervention device is defined as an engineered, single-use, or permanently implantable apparatus advanced endovascularly through the arterial tree to diagnose, revascularize, occlude, or reconstruct intracranial and extracranial vessels supplying the brain and central nervous system. Unlike open surgical craniotomy or direct microsurgical aneurysm clipping, neurovascular interventions are executed under digital subtraction angiography within dedicated hybrid operating suites or catheterization laboratories, accessing deep intracranial vascular beds via transfemoral or transradial arterial entries.
The equipment landscape is categorized into four primary operational domains based on clinical mechanics and mechanical architecture:
● Hemorrhagic Stroke Intervention Devices
Hemorrhagic stroke interventions target the structural isolation of intracranial aneurysms and arteriovenous malformations from systemic hemodynamics to eliminate wall shear stress and prevent subarachnoid hemorrhage.
- Detachable Embolization Coils: Micro-machined platinum-tungsten alloys wound into primary and secondary helical or complex 3D shapes. These implants are advanced through microcatheters into the aneurysm fundus and detached via electrolytic, mechanical, thermal, or hydraulic mechanisms to form a dense mechanical lattice that triggers thrombogenesis. Major commercial platforms include Stryker Target Coils with Ultra HD detachment, Medtronic Axium and Matrix systems, Penumbra SMART and Penumbra Coil 400 series, MicroPort NeuroTech NUMEN, NUMEN Silk, and NUMEN Nest lines, Zylox-Tonbridge Phoenix mechanical coils, Peijia Medical Jasper and Presgo systems, Kaneka i-ED Coil and ED COIL systems, and HeartCare Medical detachable coils.
- Flow Diverter Stents: Low-porosity, high-metal-surface-area tubular endoprostheses braided from nitinol and radiopaque platinum or cobalt-chromium micro-filaments. Deployed in the parent vessel across the neck of wide-neck or fusiform aneurysms, flow diverters redirect hemodynamic inflow away from the sac, creating intra-saccular blood stasis while preserving perforator artery patency, ultimately facilitating endoluminal endothelialization. Leading architectures include Medtronic Pipeline Vantage with Shield Technology and Pipeline Flex, Stryker Surpass Evolve, MicroPort NeuroTech Tubridge and Tubridge Plus, Zylox-Tonbridge Kylin, Peijia Medical YonFlow, Balt Silk Vista and Silk Vista Baby, and Sino Medical Aucura anti-thrombotic coated system compatible with 0.017-inch microcatheters.
- Intracranial Covered Stents and Aneurysm Assist Stents: Covered stent grafts, such as MicroPort NeuroTech WILLIS covered stent system, provide instantaneous exclusion of traumatic or giant pseudoaneurysms and carotid-cavernous fistulas. Braided or laser-cut scaffolding stents, such as Zylox-Tonbridge Feilong drawn filled tube assistant stent, Sino Medical laser-cut anti-thrombotic assistant stent, Cerenovus Enterprise 2, and Terumo LVIS series, secure coil masses within wide-necked bifurcations.
- Liquid Embolic Agents and Intrasaccular Disruptors: Non-adhesive polymer solutions dissolved in dimethyl sulfoxide, such as Medtronic Onyx and Balt Squid and PHIL, which precipitate upon contact with ionic aqueous blood to cast complex arteriovenous malformations. Mechanical alternatives include woven nitinol intrasaccular flow disruptors such as Terumo WEB and Zylox-Tonbridge nitinol mesh occluders, alongside bioresorbable platforms like MicroPort NeuroTech NuFairy PLGA coils.
● Ischemic Stroke Devices
These devices resolve acute large vessel occlusions within established therapeutic windows through endovascular mechanical revascularization to restore cerebral perfusion.
- Stent Retrievers: Precision laser-cut self-expanding nitinol baskets that incorporate micro-struts engineered to penetrate, integrate, and entrap organized fibrin-rich or red blood cell-rich thrombi. Platforms encompass Medtronic Solitaire X, Stryker Trevo NXT ProVue, Cerenovus EmboTrap III dual-channel system, Penumbra 3D Revascularization Device, MicroPort NeuroTech NeuroHawk and AISAdvance combo units, Zylox-Tonbridge DragonFly CRD, Peijia Medical Syphonet, HeartCare Medical Captor multi-segment radiopaque device, Balt Catch Expert, Acandis APERIO Hybrid, Wallaby Medical pREset, and Sino Medical Ghunter retriever.
- Aspiration Catheters and Vacuum Revascularization Hardware: Large-bore, highly trackable flexible catheters engineered with differential multi-zone polymer stiffness and braided or coiled steel reinforcing shafts to resist luminal collapse under extreme negative pressure. Catheters are coupled to precision electromechanical aspiration pumps or specialized vacuum syringes. Systems include Penumbra RED, JET, and ACE series, Medtronic React 68 and 71 with Riptide tubing, Cerenovus CEREGLIDE 71, MicroPort NeuroTech WAVE-track and AISFast aspiration suites, Peijia Medical Tethys AS, HeartCare Medical 088 large-bore catheter for the CATCH technique, Wallaby Medical Esperance, and Sino Medical Apachi line.
● Neurovascular Stenosis and Atherosclerotic Interventions
Targeting hemodynamically significant intracranial atherosclerotic disease and extracranial carotid and vertebral stenoses to prevent primary or recurrent embolic and hypoperfusive strokes.
- Intracranial and Vertebral Stenting Systems: Low-profile balloon-expandable and self-expanding metallic bare-metal and drug-eluting stents. Representative designs include Sino Medical NOVA and NOVA NEO, the premier commercially approved drug-eluting intracranial stent utilizing zero-polymer surface modifications to suppress restenosis; MicroPort NeuroTech APOLLO balloon-expandable intracranial stent and Bridge drug-eluting vertebral stent; HeartCare Medical self-expanding intracranial DES; and Medtronic Wingspan stent system.
- Carotid Artery Stenting and Transcarotid Neuroprotection Platforms: Devices stabilizing unstable atherosclerotic plaques in the bifurcation of the common carotid artery. Key platforms feature InspireMD CGuard EPS and CGuard Prime MicroNet mesh-covered self-expanding nitinol stents engineered to prevent intra-procedural and post-procedural plaque prolapse; Boston Scientific Carotid WALLSTENT and Silk Road Medical TCAR platform; Cordis PRECISE Pro RX and ANGIOGUARD RX system; and Acandis CARESTO heal braided carotid stent.
- Intracranial and Vertebral Balloon Catheters: Ultra-low profile, semi-compliant and non-compliant micro-balloons for pre-dilation and post-dilation of fibrous atherosclerotic lesions. Examples include Acotec Scientific NEO-Skater intracranial percutaneous transluminal angioplasty balloon and AcoArt Verbena paclitaxel-coated balloon, MicroPort NeuroTech Diveer, Peijia Medical SacSpeed and Fastunnel microcatheter-balloon combination, and Sino Medical Neuro RX and Neuro LPS systems.
● Neurovascular Access and Delivery Systems
Structural conduits providing stable mechanical access through tortuous cervical pathways into the circle of Willis.
- Steerable Balloon Guide Catheters: Positioned in the internal carotid artery to achieve temporary flow arrest during mechanical aspiration, reducing downstream clot fragment embolization. Products include MicroPort NeuroTech NeuroGuard, Zylox-Tonbridge DaYu BGC, Peijia Medical Fluxcap, HeartCare Medical Fullblock, and Sino Medical COVESTAR.
- Distal Access and Intermediate Catheters: Highly trackable, hydrophilically coated catheters delivering structural support across the carotid siphon, such as Penumbra BENCHMARK and Neuron MAX, Cordis Envoy DA, MicroPort NeuroTech X-track, Zylox-Tonbridge SilverSnake DA, and Peijia Medical Tethys.
- Microcatheters and Micro-Guidewires: Micro-engineered polyimide/PTFE lumens ranging from 0.017-inch to 0.027-inch inner diameters, paired with shapable nitinol or platinum-tungsten core wires ranging from 0.008-inch to 0.014-inch outer diameters, providing steering through tortuous tertiary cerebral branches.

DOWNSTREAM INDICATIONS AND CLINICAL CARE ARCHITECTURE
The deployment of neurovascular intervention hardware is governed by clear clinical indications and strictly regulated operating environments:
● Acute Ischemic Stroke and Large Vessel Occlusion
Accounting for roughly 80% to 85% of acute strokes worldwide, large vessel occlusions in the internal carotid artery terminus, middle cerebral artery M1/M2 segments, or basilar artery demand emergent mechanical thrombectomy within 6 to 24 hours of onset. In the United States, approximately 700,000 ischemic events manifest annually, yielding an estimated 200,000 patients eligible for mechanical thrombectomy. In China, where ischemic strokes surpass 3.0 million annually, thrombectomy penetration rates are rapidly accelerating beyond tertiary metropolitan centers into county-level medical networks.
● Intracranial Aneurysms and Subarachnoid Hemorrhage
Unruptured intracranial aneurysms exhibit an estimated general population prevalence of 2% to 3%, encompassing approximately 9 million individuals in the United States alone. When wall rupture occurs, the resulting subarachnoid hemorrhage produces 30% to 40% immediate mortality and severe neurological morbidity. Prophylactic treatment using flow diverters and intrasaccular disruption has overtaken microsurgical clipping in high-income regions due to reduced post-operative lengths of stay.
● Intracranial Atherosclerotic Disease
Intracranial stenosis accounts for 30% to 50% of stroke presentations in Asian populations, affecting an estimated 17.3 million individuals in China. Management focuses on preventing recurrent hypoperfusion through balloon angioplasty and zero-polymer drug-eluting stents tailored to withstand cerebral vascular shear forces without triggering secondary thrombosis.
● Carotid Artery Stenosis
Atherosclerotic accumulation at the carotid bifurcation represents a primary contributor to embolic transient ischemic attacks and cerebral infarctions. In the United States, high-grade carotid stenosis underpins a procedural intervention market of 155,000 operations annually, equating to an immediate 1.3 billion USD intervention market and a broader 9.3 billion USD potential addressable clinical horizon as transcarotid artery revascularization techniques supplant conventional surgical endarterectomy.
● Operating Environment Infrastructure
Neurovascular interventions require specialized clinical environments due to procedural precision demands:
- High-acuity Comprehensive Stroke Centers and Advanced Stroke Centers: Equipped with high-resolution biplane digital subtraction angiography systems, intra-procedural flat-panel computed tomography, and rapid artificial intelligence neuro-imaging triage software.
- Operating Teams: Procedures are performed exclusively by subspecialty-credentialed neurointerventional radiologists, endovascular neurosurgeons, and interventional neurologists. In China, top tier suppliers systematically maintain commercial relations across 3,800 hospital networks, ensuring complete presence within 100% of the Top 100 National Advanced Stroke Centers.

VALUE CHAIN ARCHITECTURE AND MANUFACTURING RESILIENCE
The production of neurovascular implants and access conduits involves microscopic tolerances, specialized biomaterials, and cleanroom labor:
● Upstream Raw Materials and Micro-Components
- Specialized Alloys and Core Wires: Nitinol shape-memory tubing and wire with strict transformation temperature controls, platinum-tungsten and platinum-iridium radiopaque marker bands, 316L stainless steel micro-braiding wires, and drawn filled tube wire featuring a nitinol outer mantle over a solid platinum or gold core for full-length radiopacity.
- Medical Polymers: Precision extrusions of polyether block amide, polytetrafluoroethylene liners, thermoplastic polyurethanes, high-lubricity polyimide tubing, and bioresorbable poly(lactic-co-glycolic acid) copolymers for temporary structural lattices.
- Surface Coatings and Active Pharmaceutical Ingredients: Sirolimus and paclitaxel active ingredients, hydrophilic cross-linked polyvinylpyrrolidone lubricious coatings, and covalently bonded bio-passive heparinized coatings designed to mitigate foreign body platelet reactivity.
● Midstream Manufacturing Operations
- Micro-Laser Machining and Braiding: High-precision femtosecond and picosecond laser-cutting fixtures slicing nitinol micro-tubing to sub-millimeter tolerances with minimal thermal damage. Flow diverter manufacturing relies on 48 to 72 carrier horizontal and vertical braiding machines interlacing ultra-fine metallic filaments.
- Thermo-Mechanical Heat Setting and Electropolishing: Vacuum furnace treatment utilizing custom mandrel tooling to imprint geometric memory into braided nitinol matrices, followed by chemical and electropolishing baths to eliminate surface micro-cracks, passivating titanium oxide layers.
- Cleanroom Assembly: Extensive manual microscopic fabrication under ISO Class 7 and Class 8 laminar flow environments. Technicians perform precision crimping, micro-resistance spot welding, and polymer jacket reflowing over mandrels to construct complex transition zones in 0.017-inch catheter bodies.
- Sterilization and Packaging: Double-barrier medical Tyvek packaging exposed to validated Ethylene Oxide sterilization cycles to eliminate bioburden without compromising polymer lubricity or drug integrity.
● Downstream Clinical Integration and Value Capture
Downstream models rely heavily on technical service. Manufacturers support continuous simulation labs, flow-model training circuits, and hospital consignment inventories to ensure immediate procedural readiness within Cath Labs.

COMMERCIAL DISTRIBUTION AND REIMBURSEMENT POLICY
Commercialization models in the neurovascular space reflect stark regional divergences in procurement governance, regulatory oversight, and payer architecture:
● Direct Sales Force Versus Stocking Distributor Models
- Direct Sales Infrastructure: Standard in North America and Western European territories. Medical device manufacturers field direct clinical specialists who attend live cases, provide technical sizing counsel inside the sterile field, and directly service hospital buying groups and integrated delivery networks.
- Two-Tier Distributor Networks: Dominant across China, Latin America, and the Middle East. Device developers sell capital inventories on a buyout basis to authorized master distributors who manage provincial hospital tenders, carry territorial accounts receivable, and finance institutional consignment buffers. Leading regional entities utilize extensive networks; Peijia Medical distributes across more than 2,500 Chinese medical centers via nearly one hundred dedicated field managers, while MicroPort NeuroTech maintains channel access across 36 international territories.
● Centralized Procurement and Volume-Based Tendering Dynamics
China Volume-Based Procurement frameworks have introduced systemic price rationalization:
- Centralized provincial alliances (including the Hebei multi-province alliance, Henan 15-product cohort, and regional Guangdong and Anhui consortiums) have targeted neurovascular coils, mechanical stent retrievers, flow diverters, and intermediate catheters.
- The tendering structures enforce 30% to 50% unit price reductions. However, winning enterprises receive dedicated public hospital quotas, which reduces field sales overhead, displaces sub-scale domestic competitors, and accelerates the substitution of multinational brands with qualified domestic equivalents.
● Reimbursement Coding and Coverage Evolution
- United States Inpatient Prospective Payment Logic: Neurovascular interventions fall under Medicare Severity Diagnosis Related Groups (MS-DRG 020 to 024 for intracranial vascular procedures and MS-DRG 037 to 039 for extracranial carotid revascularization). High-impact novel technologies benefit from New Technology Add-on Payments (NTAP), which offset acquisition premiums for devices demonstrating superior clinical efficacy.
- Expansion of Carotid Stenting Coverage: Centers for Medicare and Medicaid Services broadened National Coverage Determinations for transcarotid and percutaneous carotid stenting to cover standard-risk surgical and asymptomatic populations, dramatically expanding procedure authorizations.

REGIONAL MARKET DYNAMICS
● North America
North America represents the primary revenue generating geography, maintaining over 45% of total global market value.
- Procedural Density and Tech Adoption: The region is defined by rapid adoption of premium devices, fully integrated stroke network transfers, and high mechanical thrombectomy uptake. Over 200,000 annual US patients are candidates for acute large vessel recanalization.
- Premium Valuation: Premium hospital reimbursement frameworks support high average selling prices for computer-assisted vacuum thrombectomy equipment and novel surface-modified flow diverters.
- Carotid Interventions: Expanded federal coverage parameters for carotid stenting and rapid migration toward transcarotid artery revascularization techniques continue to expand procedural volumes.
● Asia-Pacific
Asia-Pacific is the second-largest neurovascular market globally and the fastest growing by procedural volume.
- China Procedural Expansion: China represents the second largest single-country market globally by value and the largest by patient eligibility. Volume expansion is propelled by aggressive construction of County Stroke Centers, hospital network consolidation, and expanding clinical coverage across Tier-2 and Tier-3 healthcare systems.
- Regional Industrial Competitiveness: Domestic Chinese manufacturers now maintain market parity across multiple intervention categories, leveraging volume-based procurement wins to dominate standard coiling and stent retrieval segments.
- Advanced Developed Markets: Japan, South Korea, Australia, and Taiwan, China display mature clinical infrastructure with rapid reimbursement inclusion for high-density braided flow diverters and next-generation intrasaccular implants.
● Europe
Europe stands as the third largest global neurovascular market.
- Centralized Healthcare Infrastructure: Adoption is sustained by universal healthcare systems, mandated hospital stroke center designations, and guideline-driven clinical trial participation.
- Regulatory Compliance: The full operational enforcement of the European Union Medical Device Regulation (EU MDR 2017/745) has raised compliance overhead, lengthening clearance timelines and favoring established European innovators and well-capitalized multinational players over small entrants.
● Latin America, Middle East, and Africa
These emerging territories represent long-term procedural expansion zones.
- Latin America: Regional procedure volumes concentrate heavily within private and public referral hubs across Brazil, Mexico, Colombia, and Argentina, characterized by bifurcated tender pricing models and gradual infrastructure modernization.
- Middle East and Africa: Expansion is driven by aggressive healthcare capital expenditures, national health initiatives, and modern hospital construction throughout Saudi Arabia, the United Arab Emirates, Turkey, and Egypt.

REGULATORY PATHWAYS AND CLINICAL TRIAL BENCHMARKS
Navigating international regulatory gates for Class III neurovascular implants represents a key operational hurdle:
● United States Food and Drug Administration Framework
- Premarket Approval Pathways: Class III neurovascular devices, including flow diverter stents, intracranial drug-eluting stents, and carotid artery mesh implants, require extensive premarket approvals backed by prospective, multi-center randomized controlled clinical trials demonstrating non-inferiority or superiority against established historical surgical or medical controls.
- Breakthrough Device Designations: The FDA has accelerated clinical assessment pathways for transformative iterations. Notable designations include Sino Medical COMETIU self-expanding intracranial drug-eluting stent in August 2025 and MicroPort NeuroTech APOLLO Dream sirolimus DES. InspireMD achieved full FDA Premarket Approval for its CGuard Prime carotid mesh stent in June 2025 based on extensive clinical trials.
● European Union Medical Device Regulation (EU MDR 2017/745)
- Heightened Notified Body Rigor: The regulatory shift from MDD to MDR requires stringent technical documentation, clinical data evaluations, continuous post-market clinical follow-up registries, and regular unannounced audits.
- International Conformity Achievements: Despite stringent testing environments, advanced international platforms have secured CE MDR certification, exemplified by Sino Medical Ghunter stent retriever in February 2026 and MicroPort NeuroTech NeuroHawk revascularization system.
● China National Medical Products Administration Framework
- Innovation Green Channel Review: The NMPA operates an expedited special approval evaluation channel for proprietary devices demonstrating significant domestic invention patent exclusivity and clear clinical necessity.
- Breakthrough Domestic Approvals: MicroPort NeuroTech NuFairy fully bioresorbable PLGA coil and StraitPass hematoma aspiration platform secured entrance into the NMPA green channel, accelerating market commercialization and local hospital adoption.

DRIVERS, DISRUPTIONS, AND BOTTLENECK RISKS
● High-Growth Market Drivers
- Computer-Assisted Vacuum Thrombectomy: Mechanical thrombectomy is shifting toward high-flow, automated large-bore aspiration platforms. Microprocessor-governed algorithms that modulate vacuum pressure in real-time reduce blood loss, limit vessel collapse, and accelerate first-pass complete recanalization without systemic thrombolysis.
- Bio-Passive and Anti-Thrombotic Coatings: The integration of non-thrombogenic surface modifications (such as Medtronic Shield Technology and Sino Medical zero-polymer electronic grafting) minimizes acute in-stent thrombosis, creating opportunities to reduce or eliminate dual antiplatelet drug regimens for fragile hemorrhagic patients.
- Interventional Brain-Computer Interfaces: Catheter-delivered intracranial endovascular electrode grids, spearheaded by developers like HeartCare Medical, leverage traditional access sheaths to position neuro-recording arrays within intracranial sinuses, enabling functional motor rehabilitation post-stroke with human trials targeting 2026.
● Operational and Structural Inhibitors
- Global Price Rationalization and Margin Degradation: Government-mandated tender pricing across China and capped public reimbursements in European territories exert downward pressure on device margins. This trend pressures single-product device developers and forces operating margins lower across mid-tier suppliers.
- Neurovascular Tortuosity and Clinical Adverse Events: Navigating the carotid siphon and delicate distal intracerebral arteries carries persistent procedural risks, including vessel perforation, acute vasospasm, arterial dissection, and distal micro-clot embolization. Addressing these challenges requires intensive physician simulator training and long learning curves.
- Intellectual Property and Cleanroom Scaling Hurdles: Strict patent protection around micro-braiding configurations, electrolytic detachment circuits, and laser-slotted geometries creates substantial barrier-to-entry walls, forcing new entrants to execute alternative engineering maneuvers or navigate complex patent infringement litigation.

CORPORATE CONSOLIDATION AND M&A DYNAMICS
Corporate merger and acquisition activities reflect clear strategic efforts to assemble comprehensive endovascular portfolios spanning access, ischemic retrieval, and hemorrhagic embolization:
- Boston Scientific Acquisition of Penumbra: In January 2026, Boston Scientific agreed to acquire Penumbra for approximately 14.500 billion USD (374 USD per share), unifying Penumbra market-leading neuro-aspiration lines and peripheral embolization technologies into Boston Scientific cardiovascular operating divisions.
- Boston Scientific Acquisition of Silk Road Medical: Executed in 2024 to lock up the proprietary transcarotid artery revascularization portfolio, giving Boston Scientific dominant control over transcarotid flow-reversal protection systems.
- Stryker Vascular Integration: Stryker integrated its Neurovascular division with newly acquired peripheral thrombectomy specialist Inari Medical to create an integrated Vascular division, achieving 1,968 million USD in net sales in fiscal 2025.

COMPETITIVE DOSSIERS: KEY INDUSTRY OPERATORS
● Stryker Corporation: Headquartered in Kalamazoo, Michigan, with primary neurovascular production operations concentrated in Fremont, California. Stryker is a global market leader in acute ischemic mechanical revascularization and cerebral aneurysm embolization hardware.
● Medtronic plc: Operating from corporate headquarters in Minneapolis, Minnesota, and Galway, Ireland, Medtronic Neurovascular possesses deep clinical trial heritage and extensive global distribution across ischemic and hemorrhagic care pathways.
● Johnson & Johnson: Cerenovus, operating as the neurovascular business unit of Johnson & Johnson MedTech from Irvine, California, bases product development on specialized clot science and endovascular stroke physics.
● Terumo Corporation: Based in Tokyo, Japan, with global neurovascular operations directed through its subsidiary MicroVention in Aliso Viejo, California. Specializes in hydrogel-coated embolic coils and intrasaccular flow disruption architecture.
● Balt Group: Located in Montmorency, France, Balt is an early neurovascular engineering enterprise founded in 1977, credited with inventing flow-directed microcatheters and chemically optimized liquid embolic agents.
● Acandis GmbH: Engineering-focused manufacturer based in Pforzheim, Germany, specializing in miniaturized neurovascular stents and anti-thrombogenic implant surfaces.
● Wallaby Medical: Cross-border medical developer maintaining headquarters in Laguna Hills, California, Shanghai, China, and Bochum, Germany, having substantially expanded global scale via the acquisition of phenox GmbH in 2022.
● InspireMD, Inc.: Based in Tel Aviv, Israel, and Boston, Massachusetts, InspireMD is focused on structural embolic prevention and carotid artery stenting systems.
● Boston Scientific Corporation: Headquartered in Marlborough, Massachusetts, Boston Scientific is an interventional device multinational that substantially expanded its neurovascular market presence via targeted multi-billion-dollar acquisitions.
● Cordis Corporation: Headquartered in Miami Lakes, Florida, Cordis possesses a deep legacy in endovascular catheterization, carotid stenting, and neurovascular vascular access.
● Kaneka Corporation: Headquartered in Tokyo and Osaka, Japan, Kaneka leverages proprietary high-performance medical polymer engineering and precision alloy fabrication through its dedicated medical intervention unit.
● MicroPort NeuroTech Limited: Headquartered in Shanghai, China, and listed on the Hong Kong Stock Exchange, MicroPort NeuroTech is the largest domestic neurovascular medical device enterprise in China, with expanding operations across Latin America, Europe, and the Middle East.
● Zylox-Tonbridge Medical Technology Co., Ltd.: Headquartered in Hangzhou, Zhejiang Province, China, and listed on the Hong Kong Stock Exchange, Zylox-Tonbridge provides complete neuro- and peripheral-vascular device portfolios under its Tonbridge franchise.
● Peijia Medical Limited (Achieva Medical): Headquartered in Suzhou and Shanghai, China, listed on the Hong Kong Stock Exchange, Peijia Medical directs its extensive neurointerventional business operations through its wholly owned subsidiary, Achieva Medical.
● HeartCare Medical (Shanghai HeartCare Medical Technology): Located in Shanghai, China, and listed on the Hong Kong Stock Exchange, HeartCare Medical is an innovative cardiovascular and neuro-interventional medical device enterprise.
● Sino Medical Sciences Technology Inc. (SINOMED): Headquartered in Tianjin, China, and listed on the Shanghai STAR Market, SINOMED applies proprietary zero-polymer electro-grafting coating science to cardiovascular and neurovascular implants.